Psychedelics in Psychiatry: Psilocybin for Treatment-Resistant Depression

From Prohibition Back to Clinical Psychiatry

After more than three decades of regulatory freeze, classic psychedelics have returned to mainstream psychiatric research at a pace few clinicians anticipated. What began in the early 2000s with small academic pilot studies has matured by 2026 into multi-center Phase 3 clinical trials, FDA Breakthrough Therapy designations, and the realistic prospect of prescription psychedelic treatments. At the center of this clinical revival stands psilocybin, the indolealkylamine prodrug produced by mushrooms of the genus Psilocybe, now the most clinically advanced classic psychedelic for mood disorders.

The historical arc is worth recalling. Throughout the 1950s and 1960s, psilocybin and lysergic acid diethylamide (LSD) were investigated in more than 1,000 clinical publications covering upwards of 40,000 patients, with encouraging signals in alcohol dependence, depressive syndromes, and existential distress in terminal illness (Grinspoon & Bakalar, 1979). That first wave of psychiatric research ended abruptly with the passage of the U.S. Controlled Substances Act of 1970, which placed psilocybin in Schedule I ("no currently accepted medical use and a high potential for abuse"), a classification driven primarily by political reaction to countercultural recreational use rather than clinical toxicology (Nutt et al., 2013).

Modern clinical investigation resumed cautiously at the turn of the century. In 2006, Roland Griffiths and colleagues at Johns Hopkins University demonstrated in a double-blind crossover study that psilocybin occasioned deeply meaningful experiences with sustained positive effects in healthy volunteers (Griffiths et al., 2006). Ten years later, randomized trials at Johns Hopkins and New York University documented rapid, durable reductions in depression and anxiety among patients with life-threatening cancer (Griffiths et al., 2016; Ross et al., 2016), while Robin Carhart-Harris and colleagues at Imperial College London published the first modern open-label feasibility trial in treatment-resistant depression (Carhart-Harris et al., 2016).

This article examines the molecular pharmacology and systems neuroscience of psilocybin, evaluates the clinical trial evidence from early pilot studies through the 2025 and 2026 Phase 3 COMP360 trials, compares its regulatory trajectory with MDMA-assisted therapy for PTSD, and weighs the methodological and safety challenges that must be resolved before routine clinical adoption.

Molecular Pharmacology and Systems Neuroscience

Serotonin 5-HT2A Receptor Agonism

Orally administered psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) acts as a prodrug that is rapidly dephosphorylated by alkaline phosphatases in the gastrointestinal tract and liver into psilocin (4-hydroxy-N,N-dimethyltryptamine), the lipid-soluble active metabolite that crosses the blood-brain barrier. Psilocin is a partial-to-full agonist at serotonin receptors with particularly high affinity for the 5-HT2A receptor ($K_i \approx 5\text{ to }7\text{ nM}$), a $G_{q/11}$-coupled receptor densely expressed on the apical dendrites of layer V pyramidal neurons across the prefrontal and association cortices (Passie et al., 2007).

Both human and preclinical studies confirm that 5-HT2A activation drives the acute subjective effects of psilocybin. Pretreatment with the selective 5-HT2A antagonist ketanserin blocks virtually all hallucinogenic and ego-dissolving effects in human volunteers (Vollenweider et al., 1998). Psilocin also binds with lower affinity to 5-HT1A, 5-HT2B, and 5-HT2C receptors; while 5-HT1A agonism modulates acute visual and autonomic responses, chronic 5-HT2B agonism is a known risk factor for cardiac valvulopathy, which reinforces the safety advantage of single-dose or episodic clinical protocols over chronic microdosing (de Vos et al., 2021).

Structural Neuroplasticity via TrkB and mTOR Signaling

A pivotal mechanistic question is why an acute pharmacological effect that clears the body within six hours can relieve depressive symptoms for weeks or months. Over the past decade, cellular neuroscience has identified structural and functional neuroplasticity as the biological bridge between acute receptor activation and durable symptom remission.

In 2018, Calvin Ly, David Olson, and colleagues demonstrated in Cell Reports that classic psychedelics act as potent "psychoplastogens," promoting neurite outgrowth, dendritic spine maturation (spinogenesis), and functional synaptogenesis in cortical neurons at rates comparable to Brain-Derived Neurotrophic Factor (BDNF) and the rapid-acting antidepressant ketamine (Ly et al., 2018). In a landmark 2023 Science study, Vargas et al. showed that lipophilic psychedelics cross the cell membrane to activate a pool of intracellular 5-HT2A receptors located on the Golgi apparatus, triggering downstream TrkB and mTOR signaling pathways that polarize dendritic spine growth even when cell-surface serotonin cannot reach those receptors (Vargas et al., 2023).

Recent work has extended these findings directly to human neural tissue. Schmidt et al. (2026) demonstrated in eLife that psilocin activates broad transcriptional neuroplasticity programs and increases excitatory synaptic density in human cortical neurons derived from induced pluripotent stem cells (iPSCs). Complementary work by Ekins et al. (2026) in Molecular Psychiatry revealed that psychedelic-induced synaptic potentiation can also propagate to cortical neurons lacking postsynaptic 5-HT2A receptors through trans-synaptic glutamate release and AMPA receptor activation.

Unlike selective serotonin reuptake inhibitors (SSRIs), which require weeks of continuous administration to gradually elevate extracellular serotonin and secondarily upregulate BDNF, a single high dose of psilocybin opens an immediate, high-amplitude window of cortical synaptic plasticity within 24 hours.

Default Mode Network Modulation and Brain Integration

At the systems level, functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG) point to a complementary network mechanism centered on the Default Mode Network (DMN). Comprising the medial prefrontal cortex, posterior cingulate cortex, precuneus, and angular gyri, the DMN is hyperactive and rigidly hyper-connected in major depressive disorder, where its activity correlates closely with self-focused depressive rumination (Hamilton et al., 2015).

Carhart-Harris et al. (2012) first showed that acute psilocybin administration desynchronizes and reduces functional connectivity within the DMN while simultaneously increasing global communication across normally segregated cortical networks. Subsequent clinical neuroimaging studies (Carhart-Harris et al., 2017; Daws et al., 2022; Gattuso et al., 2022) demonstrated that psilocybin therapy reduces modular network rigidity in depressed patients for weeks after dosing, restoring flexible global brain integration. More recently, Stoliker et al. (2026) reported in Nature that classic psychedelics shift cortical dynamics away from top-down, self-referential prior beliefs toward heightened sensitivity to bottom-up sensory and emotional context, offering a computational explanation for why patients become temporarily more receptive to cognitive and emotional reframing during therapy.

Clinical Trial Evidence: From Academic Pilots to Phase 3

Early Academic Feasibility and Cancer-Distress Trials

The modern clinical evidence base began with three influential academic studies published in 2016:

• Imperial College London open-label TRD pilot (Carhart-Harris et al., 2016): Twelve patients with moderate-to-severe treatment-resistant depression received two oral doses of psilocybin (10 mg followed one week later by 25 mg) alongside psychological preparation and integration. Depressive symptoms fell sharply at one week (mean QIDS-SR16 change of -8.0 points), with five of twelve patients achieving complete remission at three months.
• Johns Hopkins and NYU randomized cancer-distress trials (Griffiths et al., 2016, $N = 51$; Ross et al., 2016, $N = 29$): In double-blind crossover designs comparing a single high dose of psilocybin (22 to 30 mg/70 kg) against niacin or ultra-low-dose psilocybin in patients with life-threatening cancer, roughly 60 to 80 percent of participants showed clinically significant reductions in depression and existential anxiety that persisted at the 6.5-month follow-up (Cohen's $d > 0.8$).

Active Comparator Trial: Psilocybin versus Escitalopram

To test psilocybin against a standard first-line antidepressant, Carhart-Harris et al. (2021) conducted a six-week randomized, double-blind trial in The New England Journal of Medicine ($N = 59$) comparing two 25 mg psilocybin sessions plus daily placebo capsules against six weeks of daily escitalopram (10 to 20 mg) plus two 1 mg psilocybin sessions.

On the primary self-reported outcome (QIDS-SR16 at Week 6), the difference between groups (-8.0 points for psilocybin versus -6.0 points for escitalopram) did not reach statistical significance ($p = 0.17$). On clinician-rated secondary outcomes (MADRS, HAM-D-17), remission rates, and measures of emotional connectedness and social functioning, however, the psilocybin group showed substantially larger numerical improvements without the emotional blunting, sexual dysfunction, or insomnia reported in the SSRI arm. Twelve-month naturalistic follow-up data (Erritzoe et al., 2024; Henry et al., 2025) confirmed sustained symptom improvements in both cohorts alongside superior gains in psychological well-being and emotional processing in the psilocybin group.

Compass Pathways Phase 2b and Pivotal Phase 3 Trials (COMP360)

The largest registration-directed clinical program in the field is led by Compass Pathways using COMP360, a proprietary, GMP-synthesized polymorphic crystalline formulation of psilocybin for treatment-resistant depression (TRD, defined as failure of two to four prior antidepressant treatments in the current episode).

Phase 2b Dose-Ranging Trial (COMP001). Published in The New England Journal of Medicine (Goodwin et al., 2022; Rucker et al., 2022), COMP001 randomized 233 TRD patients across 22 sites in 10 countries to a single dose of COMP360 25 mg, 10 mg, or 1 mg (active low-dose control), all paired with psychological support. At the primary Week 3 endpoint, the 25 mg arm achieved a statistically significant MADRS reduction of -12.0 points compared with -5.4 points in the 1 mg control arm (between-group difference: -6.6 points, $p < 0.001$). Twenty-nine percent of patients in the 25 mg group were in remission at Week 3, compared with 8 percent in the 1 mg group. The 10 mg dose did not separate statistically from 1 mg, establishing 25 mg as the registration dose.

Pivotal Phase 3 Trial 1 (COMP005). Enrolling 258 TRD participants in a single-dose design (25 mg versus 1 mg), COMP005 met its primary endpoint at Week 6 in 2025, demonstrating a statistically significant reduction in MADRS scores for 25 mg over 1 mg. Twenty-five percent of participants in the 25 mg arm achieved a clinically meaningful response ($\ge 25%$ MADRS reduction) at Week 6, and responders maintained benefit through at least Week 26.

Pivotal Phase 3 Trial 2 (COMP006). On February 17, 2026, Compass Pathways reported positive top-line results from COMP006, its second Phase 3 trial, which evaluated two fixed doses administered three weeks apart (25 mg versus 10 mg versus 1 mg) across more than 560 participants (Compass Pathways, 2026). Two 25 mg doses produced a highly statistically significant reduction on the MADRS at Week 6 compared with the 1 mg control arm (mean between-group difference: -3.8 points, $p < 0.001$), with rapid onset evident on Day 2 and 39 percent of patients in the 25 mg arm achieving a clinically meaningful reduction at Week 6. Across more than 1,000 participants treated in the Phase 3 program, transient headache, nausea, fatigue, and mild visual disturbance resolved within 24 hours in the vast majority of cases, leading Compass to prepare a rolling New Drug Application (NDA) submission to the FDA in late 2026.

Methodological Caveats and Critical Assessment

While two positive Phase 3 trials in treatment-resistant depression mark a historic milestone for psychedelic psychiatry, a rigorous reading of the data calls for measured expectations:

1. Modest average effect sizes in multi-center Phase 3 settings. As regularly occurs in psychiatric drug development, between-group effect sizes attenuated as trials scaled from small single-center academic pilots to large multi-site Phase 3 studies. A -3.8 point MADRS separation over low-dose control in COMP006 exceeds the 2-to-3-point threshold for clinical relevance and is comparable to intranasal esketamine (Spravato, roughly -4.0 MADRS points in Phase 3 TRD trials), yet it is far from a universal cure: roughly 60 to 75 percent of TRD patients in the Phase 3 trials did not reach the response threshold from one or two sessions alone.
2. Functional unblinding and expectancy bias. A 25 mg dose of psilocybin produces unmistakable perceptual, cognitive, and emotional alterations lasting four to six hours. Even when a 1 mg dose or niacin is used as an active control, more than 90 percent of participants and therapists correctly guess treatment assignment. This functional unblinding can amplify placebo expectancy in the high-dose arm while inducing disappointment ("lessebo" or nocebo effects) among severely ill patients who realize they received the 1 mg control dose (FDA, 2024).
3. Disentangling drug from psychological support. Every clinical trial administers psilocybin within an intensive container of preparation sessions, six to eight hours of continuous interpersonal support during dosing, and post-session integration therapy. Because ethical protocols prohibit administering high-dose psychedelics to severely depressed patients without psychological support, clinical trials measure the combined efficacy of a drug-therapy dyad, not an isolated molecule.
4. Suicidality monitoring in non-responders. In the Phase 2b COMP001 trial, a small numerical imbalance in suicidal ideation and suicidal behavior emerged in the 25 mg arm compared with the 1 mg arm, predominantly among severe TRD patients whose depression failed to respond after high initial expectations. Although Phase 3 trials implemented stricter screening and follow-up safeguards, careful post-session monitoring of non-responders remains clinically vital.

Lessons from the Parallel Track: MDMA-Assisted Therapy for PTSD

The regulatory trajectory of MDMA-assisted therapy for post-traumatic stress disorder (PTSD) offers a direct cautionary lesson for psilocybin developers.

Sponsored by MAPS, two Phase 3 randomized trials published in Nature Medicine (Mitchell et al., 2021, MAPP1; Mitchell et al., 2023, MAPP2) reported large reductions in clinician-administered PTSD scores (CAPS-5), with 67 to 71 percent of MDMA-treated participants no longer meeting diagnostic criteria for PTSD at 18 weeks. Yet when Lykos Therapeutics (formerly MAPS PBC) submitted its New Drug Application, an FDA Psychopharmacologic Drugs Advisory Committee voted overwhelmingly against approval in June 2024, and the FDA issued a Complete Response Letter (CRL) in August 2024 declining to approve the application.

The FDA cited three core deficiencies: pervasive functional unblinding coupled with therapist allegiance bias, insufficient standardization of the accompanying psychotherapy, and incomplete capture of acute abuse-related and cardiovascular adverse events. Although the reorganized sponsor (Resilient Pharmaceuticals) submitted a revised response package to the FDA in August 2026 (MAPS, 2026), the 2024 rejection underscored that positive $p$-values on primary endpoints will not secure regulatory approval unless blinding, therapy standardization, and adverse-event reporting meet strict pharmaceutical standards.

Safety Profile and Potential Adverse Effects

Acute Psychological Distress

Between 10 and 30 percent of trial participants experience transient episodes of intense anxiety, fear, dysphoria, paranoia, or distressing ego dissolution during a 25 mg psilocybin session (Johnson et al., 2019). In a prepared clinical setting with trained facilitators, these episodes are almost always resolved through interpersonal reassurance without rescue medication, and often precede therapeutic breakthroughs. Outside supervised environments, however, acute panic reactions can result in erratic behavior, emergency department visits, or psychological trauma.

Extended Difficulties and HPPD

While clinical trials primarily track short-term adverse events, observational studies highlight longer-lasting risks that require systematic post-marketing surveillance:

• Extended psychological difficulties: In a large survey study, Evans et al. (2023) documented that a subset of individuals experience lingering anxiety, existential distress, derealization, or depersonalization lasting weeks to months after a challenging psychedelic experience.
• Hallucinogen Persisting Perception Disorder (HPPD): Characterized by persistent visual snow, halos, afterimages, or geometric distortions with intact reality testing, HPPD is estimated to occur in fewer than 1 percent of clinical participants vs. up to 4 percent in naturalistic polydrug cohorts (Leistenschneider et al., 2024; Majić et al., 2026).
• Mania and psychosis precipitation: Because serotonergic psychedelics can trigger manic switches or psychotic decompensation in predisposed individuals, personal or first-degree family history of schizophrenia spectrum disorders or bipolar I disorder remains a strict clinical contraindication.

Regulatory, Legal, and Healthcare Delivery Landscape

Federal Scheduling, State Frameworks, and Executive Action

In the United States, psilocybin remains a Schedule I substance under the Controlled Substances Act (and similarly restricted in Schedule I of the 1971 UN Convention on Psychotropic Substances and Anlage I of the German BtMG). Nevertheless, the regulatory environment has shifted noticeably between 2024 and 2026:

• DEA research quotas and rescheduling review**: The U.S. Drug Enforcement Administration raised its aggregate annual production quota for research-grade psilocybin from 30,000 grams in 2025 to 50,000 grams in 2026, and in August 2025 forwarded a formal rescheduling petition to the Department of Health and Human Services (HHS) for scientific and medical evaluation.
• FDA Draft Guidance (2024): The FDA's formal draft guidance on psychedelic clinical trials established clear regulatory expectations around independent blinded raters, psychotherapy standardization, abuse-potential assessment, and Risk Evaluation and Mitigation Strategies (REMS).
• Federal Executive Action (April 2026): On April 18, 2026, the White House issued a presidential directive instructing the FDA, DEA, and Veterans Health Administration to coordinate regulatory pathways for supervised access to psychedelic therapies in severe, treatment-resistant mental illness (White House, 2026).
• State-regulated service models: Outside the FDA medical model, Oregon (Measure 109, operational since 2023) and Colorado (Natural Medicine Health Act, operational since 2025) have established state-licensed psilocybin service centers, while countries such as Australia (since July 2023) permit authorized psychiatrists to prescribe psilocybin for treatment-resistant depression under tightly controlled national schemes.

Expanding Clinical Indications Beyond Depression

Beyond TRD, randomized Phase 2 trials have reported promising signals across several psychiatric and neurological conditions characterized by rigid cognitive-behavioral loops:

• Alcohol and tobacco use disorders: A double-blind randomized trial by Bogenschutz et al. (2022, $N = 95$) in JAMA Psychiatry demonstrated that two psilocybin sessions combined with motivational enhancement therapy cut heavy drinking days by more than half compared with active placebo over 32 weeks. Similarly, Johns Hopkins trials in smoking cessation reported 60 to 80 percent biologically verified abstinence at 6 to 12 months (Johnson et al., 2014, 2017).
• Obsessive-compulsive disorder (OCD) and anorexia nervosa: Phase 2a placebo-controlled data from Pellegrini et al. (2025) showed rapid reductions in acute OCD symptomatology following a single 10 mg psilocybin dose, with larger multi-dose trials underway.

Open Scientific Questions and Outlook

As psilocybin-assisted therapy approaches regulatory review, three fundamental scientific and clinical questions define the next decade of research:

First, is the conscious psychedelic experience required for the antidepressant effect? If TrkB and mTOR-mediated spinogenesis alone suffices to relieve depression, then non-hallucinogenic 5-HT2A/TrkB agonists ("non-hallucinogenic psychoplastogens" such as tabernanthalog or DLX-001; Cameron et al., 2021) could deliver rapid antidepressant efficacy as take-home oral medications without requiring eight-hour supervised clinic visits. If, conversely, the conscious psychological insight and emotional re-learning during the acute state are essential to guide how newly plastic circuits rewire, then experience-sparing analogs may prove clinically incomplete.

Second, how does psilocybin compare head-to-head with ketamine and esketamine? Both interventions rapidly induce cortical synaptogenesis, yet ketamine acts via NMDA receptor blockade and requires repeated maintenance infusions every few weeks, whereas psilocybin acts via 5-HT2A agonism and often sustains benefit for months after one or two sessions. Direct comparative effectiveness trials are urgently needed.

Third, how can health systems scale an eight-hour treatment equitably? Delivering supervised psilocybin therapy requires certified treatment rooms, multidisciplinary clinical teams, and REMS safety monitoring. Designing evidence-based group preparation models, optimizing session duration (for example, through shorter-acting tryptamines or intravenous psilocin formulations), and establishing fair insurance reimbursement will determine whether psychedelic medicine becomes an accessible psychiatric option or remains restricted to affluent self-pay patients.

The clinical evidence accumulated through 2026 leaves little doubt that psilocybin represents one of the most significant mechanistic advances in psychiatry in half a century. Realizing that promise for patients with treatment-resistant depression now depends on pairing clinical innovation with methodological rigor, honest risk communication, and disciplined post-approval safety monitoring.